Undisclosed anti-PD-L1 antibody / Tikcro Technologies, Weizmann Institute of Science - LARVOL DELTA

Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer’s disease: a phase 1b, randomized, double-blind trial. (PubMed, Nat Med) - P1 | "While Alzheimer's disease (AD) is initiated by amyloid plaque accumulation, its progression involves local neuroinflammation that the brain cannot resolve when age-related dysfunction of the systemic immune system limits peripheral immune support. The safety and tolerability profile supports further clinical development of systemic, intermittently administered IBC-Ab002 in early AD. ClinicalTrials.gov registration: NCT05551741 ."

Clinical • First-in-human • IO biomarker • Journal • P1 data • Alzheimer's Disease • CNS Disorders • Inflammation • Solid Tumor

PD-L1 blockade therapeutic effect in Tau P301S (line PS19) mouse model of tauopathy (AAIC 2023) - "Methods : Tau P301S mice were treated with anti-PD-L1 antibody, or isotype control, and tested for the functional effect of the treatment on parameters of cognitive performance and brain pathology, at different time points after treatment...Conclusions : PD-L1 blockade evokes an immune response that leads to functional improvement on cognitive performance and reduced brain pathology in Tau P301S mice. These findings, taken together with our previous reports of anti-PD-L1 therapeutic effect in other AD or tauopathy mouse models, substantiate the generalization of this treatment approach - targeting the peripheral immune system in order to drive brain tissue repair in neurodegenerative conditions."

IO biomarker • Preclinical • Alzheimer's Disease • CNS Disorders • Immune Modulation • CSF T-tau • TREM2

FIRST-IN-HUMAN CLINICAL TRIAL OF IBC-AB002, A PROPRIETARY HUMAN ANTI-PD-L1 ANTIBODY, IN PERSONS WITH EARLY ALZHEIMER’S DISEASE: TRIAL DESIGN AND OBJECTIVES. (CTAD 2022) - "Immune checkpoint blockade via inhibition of the PD-1/PD-L1 pathway is a novel and promising potential approach for modulating the adaptive immune system to treat AD, and perhaps other neurodegenerative conditions as well."

Clinical • IO biomarker • P1 data • Alzheimer's Disease • CNS Disorders • Immune Modulation • Immunology • Inflammation • Solid Tumor

Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy. (PubMed, Mol Neurodegener) - "The CCR2/CCL2 axis is required to modify pathology using PD-L1 blockade in a mouse model of tauopathy. This modification involves, in addition to monocytes, the accumulation of FOXP3 regulatory CD4 T cells in the brain, and the T-cell chemoattractant, Cxcl12."

IO biomarker • Journal • Preclinical • Alzheimer's Disease • Amyloidosis • CNS Disorders • Dementia • Immunology • Inflammation • CCL2 • CD4 • CXCL12 • FOXP3

[VIRTUAL] TRANSLATIONAL PHARMACOLOGY OF IBC- AB002, A NOVEL FULLY HUMAN ANTI-PD-L1 ANTIBODY, FOR TREATING ALZHEIMER’S DISEASE (CTAD 2020) - "IBC-Ab002 antibody, a novel engineered antibody that was selected for clinical development for treating AD, has a superior safety profile in terms of immune-related adverse events. We developed a predictive model that simulates PK/PD and efficacy in human and informs our Phase 1 clinical trial design. A first-in-human study of IBC-Ab002 in AD patients is planned for the second half of 2021."

IO Biomarker • Alzheimer's Disease • Amyloidosis • CNS Disorders • Dementia • Diabetes • Immune Modulation • Immunology • Inflammation • Metabolic Disorders • Oncology